Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study)
Crossref DOI link: https://doi.org/10.1007/s12253-017-0234-2
Published Online: 2017-04-21
Published Print: 2018-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Schneider, Tamás
Rosta, András
Losonczy, Hajna
Radványi, Gáspár
Ujj, György
Egyed, Miklós
Illés, Árpád
Jakucs, János
Szerafin, László
Gasztonyi, Zoltán
Masszi, Tamás
Iványi, János
Demeter, Judit
Dombi, Péter
Tóth, Antal
Borbényi, Zita
License valid from 2017-04-21